Pulled
SENS
back up again after a few weeks and see that it's still holding the same fib and trendline levels as it was when we first drew out the fib retracement. It's also now holding the 50DMA consistently as it steadily rises. For some context, this company develops and commercializes continuous glucose monitoring systems for diabetes patients. Senseonics offers the Eversense and Eversense XL products in its lineup. These are implantable CGM systems for measuring glucose levels with an under-skin sensor, and a removable and rechargeable smart transmitter. Sensonics also offers an app for real-time diabetes metrics monitoring.
Other Highlights:
- HC Wainwright $6 target and buy rating last month
- Collab with University Hospitals Accountable Care Organization
- Raised $50 million in gross proceeds through completion of At-the-Market equity offering program last quarter. Proceeds earmarked "primarily for debt service"
-Year-To-Date up over 320% so far
SENS
back up again after a few weeks and see that it's still holding the same fib and trendline levels as it was when we first drew out the fib retracement. It's also now holding the 50DMA consistently as it steadily rises. For some context, this company develops and commercializes continuous glucose monitoring systems for diabetes patients. Senseonics offers the Eversense and Eversense XL products in its lineup. These are implantable CGM systems for measuring glucose levels with an under-skin sensor, and a removable and rechargeable smart transmitter. Sensonics also offers an app for real-time diabetes metrics monitoring. Other Highlights:
- HC Wainwright $6 target and buy rating last month
- Collab with University Hospitals Accountable Care Organization
- Raised $50 million in gross proceeds through completion of At-the-Market equity offering program last quarter. Proceeds earmarked "primarily for debt service"
-Year-To-Date up over 320% so far
